Elicio Therapeutics在SITC会议上报告Eli-002 7P的强效细胞毒性Mkras特异性T细胞反应及Eli-004的新预临床数据

美股速递
Nov 07, 2025

Elicio Therapeutics在关于其Eli-002 7P的第二阶段Amplify-7P试验的最新进展中,报告了跨多种患者HLA的强效细胞毒性Mkras特异性T细胞反应,以及Eli-004的最新预临床数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10